Please assess the completion status of the following clinical trial:

Trial Title: Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Initial diagnosis of de novo AML with no preexisting hematologic dysplasia for more than 3 months.~* No prior therapy except leukapheresis or less than 72 hours of hydroxyurea.~Exclusion Criteria:~* Prior myelodysplastic disorder, or treatment-related leukemia.~* Prior myeloproliferative disease.~* Acute promyelocytic leukemia (APL).~* Prior chemotherapy for a malignant or nonmalignant disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).